LT3145949T - Lentivirusiniai vektoriai - Google Patents
Lentivirusiniai vektoriaiInfo
- Publication number
- LT3145949T LT3145949T LTEP15720762.2T LT15720762T LT3145949T LT 3145949 T LT3145949 T LT 3145949T LT 15720762 T LT15720762 T LT 15720762T LT 3145949 T LT3145949 T LT 3145949T
- Authority
- LT
- Lithuania
- Prior art keywords
- lentiviral vectors
- lentiviral
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18845—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mushroom Cultivation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1409089.8A GB2526339A (en) | 2014-05-21 | 2014-05-21 | Lentiviral vectors |
PCT/GB2015/051201 WO2015177501A1 (en) | 2014-05-21 | 2015-04-23 | Lentiviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3145949T true LT3145949T (lt) | 2020-08-25 |
Family
ID=51135270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP15720762.2T LT3145949T (lt) | 2014-05-21 | 2015-04-23 | Lentivirusiniai vektoriai |
Country Status (20)
Country | Link |
---|---|
US (1) | US10704061B2 (lt) |
EP (1) | EP3145949B1 (lt) |
JP (1) | JP6637444B2 (lt) |
AU (1) | AU2015263150B2 (lt) |
CA (1) | CA2947125C (lt) |
CY (1) | CY1123413T1 (lt) |
DK (1) | DK3145949T3 (lt) |
EA (1) | EA038966B1 (lt) |
ES (1) | ES2805045T3 (lt) |
GB (1) | GB2526339A (lt) |
HR (1) | HRP20200930T1 (lt) |
HU (1) | HUE051269T2 (lt) |
LT (1) | LT3145949T (lt) |
ME (1) | ME03789B (lt) |
PL (1) | PL3145949T3 (lt) |
PT (1) | PT3145949T (lt) |
RS (1) | RS60586B1 (lt) |
SI (1) | SI3145949T1 (lt) |
UA (1) | UA122127C2 (lt) |
WO (1) | WO2015177501A1 (lt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102015012334A2 (pt) | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
EP3712273A1 (en) * | 2016-04-08 | 2020-09-23 | Krystal Biotech, LLC | Compositions for the treatment of wounds, disorders, and diseases of the skin |
JP2018174874A (ja) * | 2017-04-19 | 2018-11-15 | 国立大学法人 東京医科歯科大学 | 上皮細胞の水分泌機能測定方法 |
GB201814590D0 (en) * | 2018-09-07 | 2018-10-24 | Oxford Biomedica Ltd | Viral vector production system |
CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
WO2020009444A1 (ko) * | 2018-07-02 | 2020-01-09 | 서울대학교산학협력단 | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 |
WO2020068862A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
BR112021017853A2 (pt) * | 2019-03-13 | 2021-11-30 | Generation Bio Co | Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii |
CN112575034B (zh) * | 2019-09-29 | 2023-04-25 | 济南赛尔生物科技股份有限公司 | 一种治疗a型血友病的产品及应用 |
CA3160199A1 (en) * | 2019-12-20 | 2021-06-24 | Suma Krishnan | Compositions and methods for gene delivery to the airways and/or lungs |
WO2021222222A1 (en) * | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions and methods for the treatment of cystic fibrosis |
WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
EP4162036A1 (en) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
EP4204447A1 (en) | 2020-08-28 | 2023-07-05 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
US11779660B2 (en) | 2021-04-02 | 2023-10-10 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
GB202105278D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Cell therapy |
GB202105276D0 (en) * | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Delivery of gene therapy vectors |
JP2024526850A (ja) * | 2021-07-19 | 2024-07-19 | 2セブンティ バイオ インコーポレイテッド | ベクター製造方法 |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
US20240024515A1 (en) | 2022-04-11 | 2024-01-25 | Imperial College Of Science, Technology And Medicine | Combination treatment |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
GB202212472D0 (en) * | 2022-08-26 | 2022-10-12 | Ip2Ipo Innovations Ltd | Retroviral vectors |
WO2024057315A1 (en) | 2022-09-15 | 2024-03-21 | Yeda Research And Development Co. Ltd. | Compositions and methods for virotherapy |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602705B1 (en) * | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
CN100531802C (zh) * | 2000-06-01 | 2009-08-26 | 株式会社载体研究所 | 含有血凝素活性膜蛋白质的假型逆转录病毒载体 |
EP1438399A4 (en) * | 2001-09-28 | 2005-09-14 | Univ North Carolina | PARAMYXOVIRUSES AS GENE TRANSFER VECTORS TO PULMONARY CELLS |
EP1438075A4 (en) * | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS |
KR20080068098A (ko) * | 2005-10-28 | 2008-07-22 | 디나벡크 가부시키가이샤 | Rna 바이러스 또는 dna 바이러스의 스파이크단백질로 슈도타입화된 렌티바이러스 벡터를 사용한 기도상피 간세포로의 유전자 도입 |
GB0606190D0 (en) * | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
EP1950303A1 (de) | 2007-01-26 | 2008-07-30 | Bayer CropScience AG | Genetisch modifizierte Pflanzen, die eine Stärke mit geringem Amylosegehalt und erhöhtem Quellvermögen synthetisieren |
EP3492596A1 (en) * | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
-
2014
- 2014-05-21 GB GB1409089.8A patent/GB2526339A/en not_active Withdrawn
-
2015
- 2015-04-23 PT PT157207622T patent/PT3145949T/pt unknown
- 2015-04-23 EP EP15720762.2A patent/EP3145949B1/en active Active
- 2015-04-23 WO PCT/GB2015/051201 patent/WO2015177501A1/en active Application Filing
- 2015-04-23 SI SI201531275T patent/SI3145949T1/sl unknown
- 2015-04-23 HU HUE15720762A patent/HUE051269T2/hu unknown
- 2015-04-23 RS RS20200724A patent/RS60586B1/sr unknown
- 2015-04-23 CA CA2947125A patent/CA2947125C/en active Active
- 2015-04-23 JP JP2016567082A patent/JP6637444B2/ja active Active
- 2015-04-23 EA EA201692361A patent/EA038966B1/ru unknown
- 2015-04-23 PL PL15720762T patent/PL3145949T3/pl unknown
- 2015-04-23 UA UAA201612986A patent/UA122127C2/uk unknown
- 2015-04-23 AU AU2015263150A patent/AU2015263150B2/en active Active
- 2015-04-23 DK DK15720762.2T patent/DK3145949T3/da active
- 2015-04-23 LT LTEP15720762.2T patent/LT3145949T/lt unknown
- 2015-04-23 US US15/312,026 patent/US10704061B2/en active Active
- 2015-04-23 ME MEP-2020-114A patent/ME03789B/me unknown
- 2015-04-23 ES ES15720762T patent/ES2805045T3/es active Active
-
2020
- 2020-06-10 HR HRP20200930TT patent/HRP20200930T1/hr unknown
- 2020-07-03 CY CY20201100617T patent/CY1123413T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20200930T1 (hr) | 2020-09-18 |
UA122127C2 (uk) | 2020-09-25 |
HUE051269T2 (hu) | 2021-03-01 |
JP6637444B2 (ja) | 2020-01-29 |
AU2015263150B2 (en) | 2020-04-16 |
GB201409089D0 (en) | 2014-07-02 |
SI3145949T1 (sl) | 2020-08-31 |
CA2947125C (en) | 2023-02-28 |
ES2805045T3 (es) | 2021-02-10 |
CY1123413T1 (el) | 2021-12-31 |
GB2526339A (en) | 2015-11-25 |
ME03789B (me) | 2021-04-20 |
JP2017521049A (ja) | 2017-08-03 |
RS60586B1 (sr) | 2020-08-31 |
CA2947125A1 (en) | 2015-11-26 |
EA201692361A1 (ru) | 2017-05-31 |
EA038966B1 (ru) | 2021-11-16 |
US10704061B2 (en) | 2020-07-07 |
EP3145949A1 (en) | 2017-03-29 |
WO2015177501A1 (en) | 2015-11-26 |
AU2015263150A1 (en) | 2016-11-10 |
EP3145949B1 (en) | 2020-04-08 |
US20170096684A1 (en) | 2017-04-06 |
PT3145949T (pt) | 2020-07-13 |
PL3145949T3 (pl) | 2021-01-25 |
DK3145949T3 (da) | 2020-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3145949T (pt) | Vetores lentivirais | |
GB201419865D0 (en) | Solution | |
IL239830B (en) | Case | |
GB201403684D0 (en) | Vector | |
GB201517022D0 (en) | No details | |
GB201519531D0 (en) | No details | |
GB201410907D0 (en) | No details | |
AU359704S (en) | Case | |
GB201517404D0 (en) | No details | |
GB201418217D0 (en) | No details | |
GB201418216D0 (en) | No details | |
GB201418562D0 (en) | Peptides | |
GB201517412D0 (en) | No details | |
GB201516796D0 (en) | No details | |
GB201517574D0 (en) | No details | |
GB201411230D0 (en) | Watercraft | |
GB201401877D0 (en) | Peptides | |
LT3237349T (lt) | Patobulintas biologinis rišiklis | |
HUE053256T2 (hu) | Szekvenciavariánsok | |
HK1253316A1 (zh) | 肽 | |
GB201517605D0 (en) | No details | |
GB201410910D0 (en) | No details | |
GB201622066D0 (en) | Lentiviral vectors | |
GB201420645D0 (en) | Peptides | |
GB201415450D0 (en) | Case |